Other conditions of Health Canada include that the manufacturer ensures the continued safety, efficacy and quality of the drug. The regulator has said it will closely monitor how remdesivir is prescribed to patients and take action if there is a problem.
“We appreciate Health Canada’s expedited review of Veklury (the brand name for remdesivir) in recognition of the urgent need to treat patients with COVID-19 in Canada,” said Gilead Sciences Canada CEO Melissa Koomey , in a statement Tuesday. “We are grateful for their collaboration and leadership as we work together to respond to this public health emergency. ”
The drug has received emergency or conditional clearance in some other countries, including the United States, Japan, Europe and Australia.
In Canada, some patients with COVID-19 have already been treated with remdesivir under the regulator’s special access program.